全文获取类型
收费全文 | 143720篇 |
免费 | 49563篇 |
国内免费 | 3582篇 |
专业分类
耳鼻咽喉 | 2109篇 |
儿科学 | 5286篇 |
妇产科学 | 2167篇 |
基础医学 | 23605篇 |
口腔科学 | 6242篇 |
临床医学 | 20355篇 |
内科学 | 34437篇 |
皮肤病学 | 8354篇 |
神经病学 | 16504篇 |
特种医学 | 4982篇 |
外国民族医学 | 34篇 |
外科学 | 22363篇 |
综合类 | 9473篇 |
现状与发展 | 17篇 |
一般理论 | 39篇 |
预防医学 | 8615篇 |
眼科学 | 2903篇 |
药学 | 12569篇 |
52篇 | |
中国医学 | 4144篇 |
肿瘤学 | 12615篇 |
出版年
2024年 | 183篇 |
2023年 | 929篇 |
2022年 | 2322篇 |
2021年 | 4445篇 |
2020年 | 7110篇 |
2019年 | 12542篇 |
2018年 | 12108篇 |
2017年 | 13062篇 |
2016年 | 13704篇 |
2015年 | 14351篇 |
2014年 | 15022篇 |
2013年 | 15606篇 |
2012年 | 9238篇 |
2011年 | 9410篇 |
2010年 | 12193篇 |
2009年 | 8038篇 |
2008年 | 5978篇 |
2007年 | 4918篇 |
2006年 | 4672篇 |
2005年 | 4248篇 |
2004年 | 3591篇 |
2003年 | 3324篇 |
2002年 | 3175篇 |
2001年 | 2829篇 |
2000年 | 2639篇 |
1999年 | 2005篇 |
1998年 | 918篇 |
1997年 | 889篇 |
1996年 | 725篇 |
1995年 | 603篇 |
1994年 | 534篇 |
1993年 | 359篇 |
1992年 | 688篇 |
1991年 | 585篇 |
1990年 | 534篇 |
1989年 | 466篇 |
1988年 | 379篇 |
1987年 | 382篇 |
1986年 | 303篇 |
1985年 | 243篇 |
1984年 | 192篇 |
1983年 | 142篇 |
1982年 | 88篇 |
1981年 | 106篇 |
1980年 | 77篇 |
1979年 | 129篇 |
1978年 | 88篇 |
1977年 | 69篇 |
1974年 | 83篇 |
1972年 | 99篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 应用可视化方法分析代谢组学在中医药领域的现状及趋势。方法 检索中国知网数据库(CNKI)和Web of Science 核心合集数据库2021年3月15日之前收录的中医药领域代谢组学研究的相关文献,应用CiteSpace软件对纳入的文献进行关键词、作者、研究机构等内容进行可视化分析。结果 共纳入中文文献247篇,英文文献350篇。文献数量在波动中迅速上升。中、英文文献作者合作网络显示,张爱华是中医药领域代谢组学研究发文量最多的作者,并形成了核心研究团队。发文机构显示,中国医学科学院是该领域的重要研究机构,机构间合作紧密。中、英文文献关键词分析显示,研究内容主要集中在核磁共振、代谢标记物、冠心病、质谱技术、代谢通路等相关领域。结论 中医药领域代谢组学研究的热点主要为中医药治疗代谢性疾病的机制研究。研究趋势为卵泡代谢组学研究及中药有效成分的研究。 相似文献
2.
3.
目的 分析不同特征的结直肠癌患者就医行为选择在中医院(含中西医结合医院)、西医院及肿瘤专科医院间的差异,为合理引导结直肠癌患者适宜就医及制订相关政策提供依据。方法 收集北京地区2018年1月-2019年12月17家三级甲等医院21894例首诊结直肠癌成年住院患者的病案首页数据,采用EmpowerStats 2.0对数据进行描述性分析。结果 21894例结直肠癌患者中就诊于中医院的有862例(3.93%),西医院的有8723例(39.85%),肿瘤专科医院的有12309例(56.22%)。对于不同医疗机构,男性占比均大于女性,58-68岁患者占比最大。且结直肠癌患者年龄、医疗付款方式及肿瘤分期在不同医疗机构间的分布存在差异(P<0.001)。西医院及肿瘤专科医院结直肠癌Ⅲ期患者占比最大,而就诊于中医院患者中结直肠癌Ⅳ期最多。从地域分布来看,异地就诊比例(57.32%)大于本地,且就诊于肿瘤专科医院的患者中73.66%来自外地。患者来源前三名分别是北京市、河北省及内蒙古自治区。而在北京市内,西医院患者主要来源于朝阳区、海淀区及西城区,中医院患者主要来源于海淀区、朝阳区及丰台区,肿瘤专科医院则主要来源于朝阳区、海淀区及丰台区。结论 应大力倡导年轻以及早期结直肠癌患者向中医院分流,充分施展中医药在结直肠癌患者中的治疗优势;发挥三级医院带动作用,建立对口帮扶医院,减少不必要的跨省流动及提倡结直肠癌的早筛早治,以降低结直肠癌死亡率。 相似文献
4.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
5.
6.
7.
Weina Cheng Yazhi Wang Jingxian Liu Xiaofei Li Ming Yu Cancan Duan Liu Liu Jianyong Zhang 《Journal of applied toxicology : JAT》2022,42(6):970-980
Cantharidin (CTD) is an effective antitumor agent. However, it exhibits significant hepatotoxicity, the mechanism of which remains unclear. In this study, biochemical and histopathological analyses complemented with ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS)-based targeted metabolomic analysis of bile acids (BAs) were employed to investigate CTD-induced hepatotoxicity in rats. Sixteen male and female Sprague–Dawley rats were randomly divided into two groups: control and CTD (1.0 mg/kg) groups. Serum and liver samples were collected after 28 days of intervention. Biochemical, histopathological, and BA metabolomic analyses were performed for all samples. Further, the key biomarkers of CTD-induced hepatotoxicity were identified via multivariate and metabolic pathway analyses. In addition, metabolite–gene–enzyme network and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to identify the signaling pathways related to CTD-induced hepatotoxicity. The results revealed significantly increased levels of biochemical indices (alanine aminotransferase, aspartate aminotransferase, and total bile acid). Histopathological analysis revealed that the hepatocytes were damaged. Further, 20 endogenous BAs were quantitated via UHPLC-MS/MS, and multivariate and metabolic pathway analyses of BAs revealed that hyocholic acid, cholic acid, and chenodeoxycholic acid were the key biomarkers of CTD-induced hepatotoxicity. Meanwhile, primary and secondary BA biosynthesis and taurine and hypotaurine metabolism were found to be associated with the mechanism by which CTD induced hepatotoxicity in rats. This study provides useful insights for research on the mechanism of CTD-induced hepatotoxicity. 相似文献
8.
9.